| Current Price | $257.01 | Mkt Cap | $43.3B |
|---|---|---|---|
| Open | $258.53 | P/E Ratio | 14.00 |
| Prev. Close | $257.01 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $255.25 - $259.23 | Volume | 887,737 |
| 52-Wk Range | $250.31 - $319.76 | Avg. Daily Vol. | 1,006,254 |
The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.
| Current Price | $257.01 | Mkt Cap | $43.3B |
|---|---|---|---|
| Open | $258.53 | P/E Ratio | 14.00 |
| Prev. Close | $257.01 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $255.25 - $259.23 | Volume | 887,737 |
| 52-Wk Range | $250.31 - $319.76 | Avg. Daily Vol. | 1,006,254 |
The best Bull and Bear pitches based on recency and number of recommendations.
Biogen is beat down because of all of the controversy surrounding its Alzheimer’s drug. It is now actually worth $50/share less since Aduhelm Was approved. It is at a 5 year low. The company would probably actually have a higher market cap if Aduhelm… More
Seems like the poor testing process control or outright fraud might be systemic within the company - kind of like the pharma version of Boeing MAX.
Read the most recent pitches from players about BIIB.
Recs
BayouBink
(29.16)
Submitted: 1/12/2022 6:09:06 AM :
Start Price:
$220.30
NASDAQ:BIIB Score:
+25.73
Biogen is beat down because of all of the controversy surrounding its Alzheimer’s drug. It is now actually worth $50/share less since Aduhelm Was approved. It is at a 5 year low. The company would probably actually have a higher market cap if Aduhelm had bee rejected, which makes zero sense.
Recs
TMFSecurity
(93.06)
Submitted: 11/16/2021 9:09:05 AM :
Start Price:
$268.27
NASDAQ:BIIB Score:
-4.06
10000000146
Recs
TMFAdriaCimino
(< 20)
Submitted: 10/12/2021 5:54:34 AM :
Start Price:
$285.48
NASDAQ:BIIB Score:
-8.31
I think Biogen is at a turning point. The company's blockbuster MS revenue is declining. But it has several potential products in phase 3 studies in various treatment areas. I expect Biogen to return to growing revenue and profit as new products come to market.
Find the members with the highest scoring picks in BIIB.
optioncoach (90.64) Score: +637.71
The Score Leader is the player with the highest score across all their picks in BIIB.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| fwhittlesey | < 20 | 4/12/2007 |
|
3Y | $43.64 | +487.51% | +214.42% | +273.09 | 1 Comment | |
| tradersinsights | 54.96 | 4/10/2007 |
|
1Y | $44.42 | +477.19% | +212.75% | +264.45 | 1 Comment | |
| anewday101 | 90.53 | 3/5/2007 |
|
1Y | $43.36 | +491.31% | +228.97% | +262.34 | 0 Comment | |
| ambina | < 20 | 3/12/2007 |
|
NS | $43.95 | +483.37% | +222.14% | +261.22 | 0 Comment | |
| nickysone | 68.94 | 4/9/2007 |
|
3Y | $44.86 | +471.53% | +212.44% | +259.09 | 1 Comment | |
| mgroeber | < 20 | 4/9/2007 |
|
NS | $44.86 | +471.53% | +212.44% | +259.09 | 0 Comment | |
| mtung | 64.88 | 3/8/2007 |
|
NS | $44.10 | +481.38% | +222.84% | +258.54 | 0 Comment | |
| Actionman2go | 64.60 | 4/13/2007 |
|
3Y | $45.00 | +469.76% | +212.10% | +257.65 | 1 Comment | |
| apple1jam | 75.15 |
|
|
NS | $43.94 | +483.50% | +226.94% | +256.56 | 0 Comment | |
| tlop1 | < 20 | 5/18/2007 |
|
3Y | $46.51 | +451.26% | +197.31% | +253.95 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
